<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>384</serviceExecutionTime><Drug id="50558"><DrugName>MAb therapeutics (cancer), AGY Therapeutics</DrugName><DrugSynonyms><Name><Value>anti-AGY-401 MAb, AGY Therapeutics</Value></Name><Name><Value>anti-AGY-402 MAb, AGY Therapeutics</Value></Name><Name><Value>anti-AGY-403 MAb, AGY Therapeutics</Value></Name><Name><Value>anti-RPTP zeta MAb, AGY Therapeutics</Value></Name><Name><Value>MAb therapeutics (cancer), AGY Therapeutics</Value></Name></DrugSynonyms><CompanyOriginator id="28161">AGY Therapeutics Inc</CompanyOriginator><CompaniesSecondary><Company id="28161">AGY Therapeutics Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="28161" type="Company"><TargetEntity id="4296291490" type="organizationId">AGY Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="1108" type="ciIndication"><TargetEntity id="10018338" type="MEDDRA"></TargetEntity><TargetEntity id="D005910" type="MeSH"></TargetEntity><TargetEntity id="-1503483999" type="omicsDisease"></TargetEntity><TargetEntity id="680" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="1108">Glioma</Indication><Indication id="725">Solid tumor</Indication></IndicationsSecondary><ActionsSecondary><Action id="55685">Anticancer monoclonal antibody</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="51">Monoclonal antibody</Technology></Technologies><LastModificationDate>2017-08-16T11:06:37.000Z</LastModificationDate><ChangeDateLast>2009-05-27T11:29:19.000Z</ChangeDateLast><AddedDate>2004-06-21T11:17:48.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="28161" linkType="Company"&gt;AGY Therapeutics&lt;/ulink&gt; was investigating monoclonal antibodies (MAbs) against three selected surface antigen targets, AGY-401, AGY-402, AGY-403, for the potential treatment of glioblastoma and other solid tumor types. In April 2004, in vivo studies were ongoing which at that time were expected to be complete by mid-2004. At that time, the company anticipated seeking a development and licensing partner upon completion of in vivo studies [&lt;ulink linkID="539439" linkType="reference"&gt;539439&lt;/ulink&gt;]; however, by May 2009, the company was no longer trading and all research and development activities were presumed to have been discontinued [&lt;ulink linkID="1012815" linkType="Reference"&gt;1012815&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2002, AGY disclosed that it had identified highly specific targets that could lead to new treatments for glioblastoma. The most promising target was AGY-401, receptor tyrosine phosphatase zeta (RPTP zeta), which is covered by US-06455026 [&lt;ulink linkID="471533" linkType="reference"&gt;471533&lt;/ulink&gt;], [&lt;ulink linkID="507535" linkType="reference"&gt;507535&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="28161">AGY Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-05-22T00:00:00.000Z</StatusDate><Source id="1012815" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28161">AGY Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1108">Glioma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-05-22T00:00:00.000Z</StatusDate><Source id="1012815" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="28161">AGY Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1108">Glioma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-04-06T00:00:00.000Z</StatusDate><Source id="539439" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28161">AGY Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-04-06T00:00:00.000Z</StatusDate><Source id="539439" type="OTHER"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>